{"groups":[{"description":"Patients receive oral l-glutamic acid hydrocloride 3 times daily beginning prior to the first dose of vincristine and continuing through week 5 (stratum 2) or week 10 (stratum 1). Patients with a body surface area (BSA) less than 1.0 m\\^2 will receive a total of 750 mg/day of oral glutamic acid . Patients with a body surface area (BSA) greater or equal to1.0 m\\^2 will receive a total of 1500 mg/day of oral glutamic acid .","id":"FG000","title":"Arm I Glutamic Acid"},{"description":"Patients receive oral placebo 3 times daily beginning prior to the first dose of vincristine and continuing through week 5 (stratum 2) or week 10 (stratum 1). Placebo capsules are identical in appearance to the active oral glutamic acid capsules but instead each capsule contains 324 mg of microcrystalline cellulose as a filler, 3 mg of magnesium stearate as a lubricant and 3 mg silicone dioxide as a drying agent for a total fill weight of 330 mg. The manufacturer has certified that the placebo contains no active agent.\n\nPatients with a body surface area (BSA) less than 1.0 m\\^2 will receive a 1 capsule of placebo 3 times daily (total 3 capsules daily). Patients with a body surface area (BSA) greater or equal to1.0 m\\^2 will receive a 2 placebo capsules 3 times daily (total 6 capsules daily). .","id":"FG001","title":"Arm II Placebo"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"127"},{"groupId":"FG001","numSubjects":"123"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"84"},{"groupId":"FG001","numSubjects":"100"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"43"},{"groupId":"FG001","numSubjects":"23"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}